<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043766</url>
  </required_header>
  <id_info>
    <org_study_id>PF614-102</org_study_id>
    <nct_id>NCT05043766</nct_id>
  </id_info>
  <brief_title>Evaluation of Oral PF614 Relative to OxyContin</brief_title>
  <official_title>A Phase 1b, Randomized 2-Part Single-Center Study to Evaluate the PK and Safety of Multiple Ascending Oral Doses of PF614 and the Food Effect and BA/BE of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ensysce Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ensysce Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A)&#xD;
      and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B). Both parts&#xD;
      of the study will be conducted in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to evaluate the pharmacokinetics of OxyContin (oxycodone ER) and&#xD;
      PF614, as well as PF614 fragments, following administration of multiple ascending doses of&#xD;
      PF614, and to compare to steady-state pharmacokinetics to those of OxyContin. (Part A)&#xD;
&#xD;
      In addition, oral bioavailability of oxycodone derived from single doses of PF614 of the&#xD;
      to-be-marketed capsule formulation will be compared to that of the reference drug, OxyContin,&#xD;
      in the fasted and fed condition. A pivotal food effect assessment will be incorporated into&#xD;
      the study to determine the impact of a high fat meal on the bioavailability of oxycodone,&#xD;
      following oral single-dose administration of PF614 (Part B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part A will utilize a randomized, open label, multiple-ascending dose design with up to 3 separate dose groups of 8 subjects per group.&#xD;
Part B will utilize an open-label, single-dose, randomized, 4-way crossover design with 13 subjects in each treatment sequence.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse Events, Significant Adverse Events, Adverse Events leading to discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics AUC [Area Under the Curve]</measure>
    <time_frame>Full PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Area under the concentration-time curve from the time of dosing to the start of the next dosing interval using PF614 concentrations and oxycodone concentrations in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Cmax [Maximum Plasma Concentration]</measure>
    <time_frame>PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Maximum (peak) plasma concentration first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Tlag [Time to first measurable plasma concentration]</measure>
    <time_frame>PK sampling time points will be 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Time prior to the time corresponding to the first measurable (non-zero) concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Tmax [Time to maximum plasma concentration]</measure>
    <time_frame>PK sampling time points 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Time to maximum plasma concentration on Day 1 (first dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics AUC, Steady State</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Steady-state (Day 5) area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics CL/F [Clearance]</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Apparent total systemic clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Cmax, Steady State</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Maximum (peak) plasma concentration at steady-state on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Tmax, Steady State</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Time to maximum plasma concentration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics t1/2 [Half-life]</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Vz/F [Volume of Distribution]</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Apparent volume of distribution during the terminal-elimination phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics elimination rate</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Terminal elimination rate/constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Ctrough [Minimum Plasma Concentration before next dose]</measure>
    <time_frame>Prior to dosing on Days 2, 3, and 4</time_frame>
    <description>Concentrations prior to dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Part B AUC</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Area under the concentration-time curve from the time of dosing extrapolated to time infinity in fed vs fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Part B AUC 0-t</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Area under the concentration-time curve from the time of dosing to the last measurable concentration in fed vs fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Part B Cmax</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Maximum (peak) plasma concentration in fed vs fasted state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability and Bioequivalence</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Bioavailability and Bioequivalence of single oral doses of PF614 prodrug and oxycodone derived from from PF614 vs. oxycodone derived from OxyContin in healthy adult subjects (Part B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Part B CL/F</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Part B pAUC</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Partial area under the concentration-time curve from the time of dosing to 12 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Part B Tlag</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Time prior to the time corresponding to the first measurable dose (non-zero) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Part B Tmax</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Time to maximum plasma concentration on Day 1 (first dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Part B t1/2</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Terminal elimination half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Part B Vz/F</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Part B Terminal elimination rate</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of inactive metabolic fragment #1</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Evaluate plasma concentrations of PFR06082 (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of inactive metabolic fragment #2</measure>
    <time_frame>PK sampling time points 0, 30 minutes; 1, 2, 3, 4, 6, 8, and 12 hours</time_frame>
    <description>Evaluate plasma concentrations of PFR06110 (Part A only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>PF614</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A will utilize a randomized, open-label, multiple-ascending dose design with up to 3 separate dose groups of 8 subjects. Within each dose group, subjects will be randomized to receive repeated BID doses, planned to be 12 hours apart over a 5 day period, for a total of 9 doses. Dose escalation to Dose Groups 2 and 3 will follow a review of pharmacokinetic, safety and tolerability data up to Day 10 of the preceding group. The doses or dosing regimen for Dose groups 2 and 3 may be modified based on a review of the data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Compare Bioavailability and Bioequivalence</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part B will utilize an open-label, single-dose, randomized, 4-way crossover design. Following confirmation of eligibility, subjects will be randomized to receive each of the single oral doses of study drugs (one at each treatment period).&#xD;
PF614 100 mg administered under fasted conditions; PF614 100 mg administered under fed conditions; OxyContin 40 mg administered under fasted conditions; OxyContin 40 mg administered under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF614</intervention_name>
    <description>PF614 is an oxycodone prodrug</description>
    <arm_group_label>PF614</arm_group_label>
    <arm_group_label>Part B Compare Bioavailability and Bioequivalence</arm_group_label>
    <other_name>oxycodone prodrug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone Hydrochloride</intervention_name>
    <description>Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers</description>
    <arm_group_label>PF614</arm_group_label>
    <arm_group_label>Part B Compare Bioavailability and Bioequivalence</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OxyContin</intervention_name>
    <description>Bioequivalence single-dose comparison to OxyContin</description>
    <arm_group_label>Part B Compare Bioavailability and Bioequivalence</arm_group_label>
    <other_name>OxyContin 40 mg Extended-Release Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, ages 18-50 years in good general health,&#xD;
&#xD;
          -  BMI between 18 and 32 kg/m (inclusive)&#xD;
&#xD;
          -  Subjects must have a negative screen for drugs of abuse, nicotine, alcohol, Hepatitis&#xD;
             B, Hepatitis C, and HIV.&#xD;
&#xD;
          -  Female subjects of child bearing potential must have a negative serum pregnancy test&#xD;
             at randomization&#xD;
&#xD;
          -  Females must be of non-child bearing potential (e.g. postmenopausal) or of&#xD;
             childbearing potential and agree to use a highly effective form of contraception from&#xD;
             the time of screening to two weeks after last dose of study medication.&#xD;
&#xD;
          -  Subjects must have normal findings in a physical examination and 12 lead ECG and&#xD;
             normal Vital Signs&#xD;
&#xD;
          -  Clinical laboratory values must be Within Normal limits as defined by the clinical&#xD;
             laboratory&#xD;
&#xD;
          -  Subjects must be able to provide coherent written informed consent&#xD;
&#xD;
          -  Subjects must be willing and able to follow study instructions and be likely to&#xD;
             complete all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy or sensitivity to oxycodone&#xD;
&#xD;
          -  History of loud snoring or sleep apnea&#xD;
&#xD;
          -  History of medical problems encountered with opioid therapy&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history of smoking or regular tobacco&#xD;
             use with 2 months prior to screening&#xD;
&#xD;
          -  History of alcoholism or drug abuse&#xD;
&#xD;
          -  Use of prescription medications within 14 days of study drug administration with&#xD;
             exception of contraceptives used by female subjects&#xD;
&#xD;
          -  Use of any opioid within 30 days prior to screening&#xD;
&#xD;
          -  History of allergy or sensitivity to naltrexone&#xD;
&#xD;
          -  History of allergy or sensitivity to naloxone&#xD;
&#xD;
          -  Donation of blood within 30 days prior to screening&#xD;
&#xD;
          -  Donation of plasma within 30 days prior to screening&#xD;
&#xD;
          -  Acute illness at admission of clinical study unit&#xD;
&#xD;
          -  History of GI disturbance requiring use of antacid twice weekly or more&#xD;
&#xD;
          -  Females who are breastfeeding&#xD;
&#xD;
          -  Anticipated need for surgery or hospitalization during the study&#xD;
&#xD;
          -  Enrollment in an investigational drug study within 30 days prior to screening&#xD;
&#xD;
          -  Any condition that in the Investigator's opinion puts the subject at significant risk,&#xD;
             could confound the study results, or may interfere significantly with the subject's&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William K Schmidt, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Ensysce Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William K Schmidt, PhD</last_name>
    <phone>650-438-3018</phone>
    <email>schmidtwk@sbcglobal.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynn Kirkpatrick, PhD</last_name>
    <phone>858-263-4196</phone>
    <email>lkirkpatrick@ensysce.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PRA Health Sciences-Early Development Services</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Ventrello</last_name>
      <phone>801-269-8200</phone>
      <email>ventrellochristian@prahs.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prodrug</keyword>
  <keyword>PF614</keyword>
  <keyword>OxyContin</keyword>
  <keyword>oral</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

